Study Dynamic Haptic Robotic Trainer (DHRT) and DHRT+ for Central Venous Catheterization Insertion Training for Residents

October 9, 2026 updated by: Scarlett Miller, Milton S. Hershey Medical Center

Study Dynamic Haptic Robotic Trainer (DHRT) and DHRT+ for Central Venous Catheterization Insertion Training for Surgical Residents

Human participants will include medical residents. Each year, the entering first-year medical residents at Milton S. Hershey Medical Center and Cedars-Sinai Medical Center will be taught to perform central venous catheterization using the Dynamic Haptic Robotic Trainer (DHRT) or the Advanced Dynamic Haptic Robotic Trainer (DHRT+). The resident's performance will be measured and evaluated by these devices during training. The technique of the training does not differ from what is currently taught at either institution. Residents will be required to pass the same skills assessment currently required at their institution. Upon successfully passing the skills assessment, residents will perform central venous catheterization procedures under supervision. The investigators will examine patient files at Milton S. Hershey Medical Center to determine changes in central line-related complication and infection rates associated with the introduction of these training devices.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
773

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Pennsylvania
      • Hershey, Pennsylvania, United States, 17033
        • Hershey Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

First-year resident undergoing central venous catheterization training at Milton S. Hershey Medical Center or Cedars-Sinai Medical Center, at least 18 years of age

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Residents to receive Dynamic Haptic Robotic Training

First-year residents at Milton S. Hershey Medical Center or Cedars Sinai Medical Center trained using the Dynamic Haptic Robotic Trainer (DHRT), a device that trains residents to safely perform the needle insertion component of central venous catheterization."
Other: Dynamic Haptic Robotic Trainer (DHRT)

Device trains medical residents to safely perform the needle insertion portion of Central Venous Catheterization.
Experimental: Residents to receive Advanced Dynamic Haptic Robotic Training

First-year residents at Milton S. Hershey Medical Center or Cedars Sinai Medical Center trained using the Advanced Dynamic Haptic Robotic Trainer (DHRT+), which offers whole-procedure training.
Other: Advanced Dynamic Haptic Robotic Trainer (DHRT+)

Device offers whole procedural training for medical residents to safely perform the procedure of Central Venous Catheterization.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Number of Internal Jugular Central Venous Catheters With and Without Mechanical Complication
Time Frame: Residents trained in 2021 (tracked insertion year 2022) for the DHRT period; residents trained in 2022-2024 (tracked insertion years 2023-2025) for the DHRT+ period.

Mechanical complications were defined as a composite outcome including hematoma, arterial puncture, pneumothorax, hemothorax, catheter misplacement, and vessel stenosis, identified using diagnosis codes from the International Classification of Diseases that were flagged as not present at the time of hospital admission. Outcome data reflects retrospective chart review at Milton S. Hershey Medical Center. DHRT deployment began June 2021; DHRT+ began June 2022. Data collection is complete.
Residents trained in 2021 (tracked insertion year 2022) for the DHRT period; residents trained in 2022-2024 (tracked insertion years 2023-2025) for the DHRT+ period.
Number of Internal Jugular Central Venous Catheters With and Without Thrombotic Complication
Time Frame: Residents trained in 2021 (tracked insertion year 2022) for the DHRT period; residents trained in 2022-2024 (tracked insertion years 2023-2025) for the DHRT+ period.

Thrombotic complications were defined as venous or arterial thrombosis, including catheter-associated device thrombosis, identified using diagnosis codes from the International Classification of Diseases that were flagged as not present at the time of hospital admission. Outcome data reflects retrospective chart review at Milton S. Hershey Medical Center. DHRT deployment began June 2021; DHRT+ began June 2022. Data collection is complete.
Residents trained in 2021 (tracked insertion year 2022) for the DHRT period; residents trained in 2022-2024 (tracked insertion years 2023-2025) for the DHRT+ period.
Number of Internal Jugular Central Venous Catheters With and Without Infectious Complication
Time Frame: Residents trained in 2021 (tracked insertion year 2022) for the DHRT period; residents trained in 2022-2024 (tracked insertion years 2023-2025) for the DHRT+ period.

Infectious complications were defined as a composite outcome including catheter-site infection and central line-associated bloodstream infection, identified using diagnosis codes from the International Classification of Diseases that were flagged as not present at the time of hospital admission. Outcome data reflects retrospective chart review at Milton S. Hershey Medical Center. DHRT deployment began June 2021; DHRT+ began June 2022. Data collection is complete.
Residents trained in 2021 (tracked insertion year 2022) for the DHRT period; residents trained in 2022-2024 (tracked insertion years 2023-2025) for the DHRT+ period.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Milton S. Hershey Medical Center

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
National Heart, Lung, and Blood Institute (NHLBI)

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Scarlett R Miller, Ph.D., Penn State University
  • Principal Investigator: Jason Z. Moore, Ph.D., Penn State University
  • Study Director: Sanaz Motamedi, PhD, Penn State University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 19, 2020

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 31, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 30, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 24, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 1, 2020

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 9, 2020

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 4, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 9, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • STUDY00012206
  • R01HL127316 (U.S. NIH Grant/Contract)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings